195 related articles for article (PubMed ID: 22246208)
1. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients.
Bagnoli M; De Cecco L; Granata A; Nicoletti R; Marchesi E; Alberti P; Valeri B; Libra M; Barbareschi M; Raspagliesi F; Mezzanzanica D; Canevari S
Oncotarget; 2011 Dec; 2(12):1265-78. PubMed ID: 22246208
[TBL] [Abstract][Full Text] [Related]
2. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
4. A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.
Calura E; Paracchini L; Fruscio R; DiFeo A; Ravaggi A; Peronne J; Martini P; Sales G; Beltrame L; Bignotti E; Tognon G; Milani R; Clivio L; Dell'Anna T; Cattoretti G; Katsaros D; Sartori E; Mangioni C; Ardighieri L; D'Incalci M; Marchini S; Romualdi C
Ann Oncol; 2016 Aug; 27(8):1511-9. PubMed ID: 27194815
[TBL] [Abstract][Full Text] [Related]
5. Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.
Yoshida K; Yokoi A; Sugiyama M; Oda S; Kitami K; Tamauchi S; Ikeda Y; Yoshikawa N; Nishino K; Niimi K; Suzuki S; Kikkawa F; Yokoi T; Kajiyama H
Oncogene; 2021 Feb; 40(7):1255-1268. PubMed ID: 33420363
[TBL] [Abstract][Full Text] [Related]
6. Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Lee YS; Cho YL
Anticancer Res; 2015 May; 35(5):2611-7. PubMed ID: 25964536
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL
Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653
[TBL] [Abstract][Full Text] [Related]
8. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
9. MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.
Calura E; Fruscio R; Paracchini L; Bignotti E; Ravaggi A; Martini P; Sales G; Beltrame L; Clivio L; Ceppi L; Di Marino M; Fuso Nerini I; Zanotti L; Cavalieri D; Cattoretti G; Perego P; Milani R; Katsaros D; Tognon G; Sartori E; Pecorelli S; Mangioni C; D'Incalci M; Romualdi C; Marchini S
Clin Cancer Res; 2013 Aug; 19(15):4114-23. PubMed ID: 23766361
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
11. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
[TBL] [Abstract][Full Text] [Related]
12. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.
Teng Y; Su X; Zhang X; Zhang Y; Li C; Niu W; Liu C; Qu K
Oncotarget; 2016 Dec; 7(49):81621-81633. PubMed ID: 27835595
[TBL] [Abstract][Full Text] [Related]
13. Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy.
Bachvarov D; L'esperance S; Popa I; Bachvarova M; Plante M; Têtu B
Int J Oncol; 2006 Oct; 29(4):919-33. PubMed ID: 16964388
[TBL] [Abstract][Full Text] [Related]
14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
15. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer.
Biamonte F; Santamaria G; Sacco A; Perrone FM; Di Cello A; Battaglia AM; Salatino A; Di Vito A; Aversa I; Venturella R; Zullo F; Costanzo F
Sci Rep; 2019 Apr; 9(1):5668. PubMed ID: 30952937
[TBL] [Abstract][Full Text] [Related]
17. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
18. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
19. Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer.
Liu L; Zou J; Wang Q; Yin FQ; Zhang W; Li L
Tumour Biol; 2014 Aug; 35(8):7713-7. PubMed ID: 24805828
[TBL] [Abstract][Full Text] [Related]
20. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
